Assisted reproductive technology and ovarian cancer

被引:1
|
作者
Devesa, M. [1 ]
Barri, P. N. [1 ]
Coroleu, B. [1 ]
机构
[1] Inst Univ Dexeus, Serv Reprod Med, Dept Obstet Gynecol & Reprod, Barcelona 08028, Spain
关键词
Ovarian neoplasms; Infertility; Fertility agents; Ovulation induction; IN-VITRO FERTILIZATION; ORAL-CONTRACEPTIVE USE; TERM-FOLLOW-UP; FERTILITY DRUGS; OVULATION INDUCTION; INFERTILE WOMEN; RISK; STIMULATION; COHORT; BREAST;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ovarian cancer has the highest mortality among all gynaecological cancers, being multiparity and oral contraceptive use the most important protective factors. According to both the "incessant ovulation" and "increased gonadotrophin" theories, fertility drugs might hive an association with the development of ovarian cancer, as has been reported by some studies. However, infertility and nulliparity may act as confounding factors and most studies regarding this issue are hampered by methodological limitations. It seems that female infertility may be associated with a modest increase in ovarian cancer risk in those patients who remain nulligravid despite long periods of unprotected intercourse. Globally, most studies are reassuring in not showing a link between the use of fertility drugs and an increased risk of ovarian cancer. Nonetheless, further research in well-designed studies is warranted.
引用
收藏
页码:247 / 257
页数:11
相关论文
共 50 条
  • [21] Assisted reproductive technology. ovarian hyperstimulation syndrome and obstetrical outcome
    Schenker, JG
    PERINATAL MEDICINE OF THE NEW MILLENNIUM, 2001, : 54 - 63
  • [22] Impact of gonadotrophin stimulation for assisted reproductive technology on ovarian ageing and menopause
    Elder, Kay
    Mathews, Thomas
    Kutner, Ellen
    Kim, Eujin
    Espenberg, Donna
    Faddy, Malcolm
    Gosden, Roger
    REPRODUCTIVE BIOMEDICINE ONLINE, 2008, 16 (05) : 611 - 616
  • [23] Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology
    Racca, Annalisa
    Drakopoulos, Panagiotis
    Raquel Neves, Ana
    Polyzos, Nikolaos P.
    DRUGS, 2020, 80 (10) : 973 - 994
  • [24] Prothrombotic biomarkers during controlled ovarian stimulation for assisted reproductive technology
    Hugon-Rodin, Justine
    Casini, Alessandro
    Benard, Julie
    Poncet, Antoine
    Raverot, Veronique
    Fontana, Pierre
    Vulliemoz, Nicolas
    Streuli, Isabelle
    FERTILITY AND STERILITY, 2023, 119 (06) : 976 - 984
  • [25] Risk of Preeclampsia in Pregnancies After Assisted Reproductive Technology and Ovarian Stimulation
    Angela S. Martin
    Michael Monsour
    Jennifer F. Kawwass
    Sheree L. Boulet
    Dmitry M. Kissin
    Denise J. Jamieson
    Maternal and Child Health Journal, 2016, 20 : 2050 - 2056
  • [26] Concentrations of ovarian proteohormones as biological markers for the outcome of assisted reproductive technology
    Casper, FW
    Seufert, RJ
    Schaffrath, M
    Pollow, K
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2002, 28 (01) : 26 - 31
  • [27] Severity of Diminished Ovarian Reserve and Chance of Success with Assisted Reproductive Technology
    Kawwass, Jennifer Fay
    Boulet, Sheree L.
    Hipp, Heather S.
    Session, Donna R.
    Kissin, Dmitry M.
    Jamieson, Denise J.
    JOURNAL OF REPRODUCTIVE MEDICINE, 2017, 62 (3-4) : 153 - 160
  • [28] Biological versus chronological ovarian age: implications for assisted reproductive technology
    Alviggi, Carlo
    Humaidan, Peter
    Howles, Colin M.
    Tredway, Donald
    Hillier, Stephen G.
    REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2009, 7 : 101
  • [29] Hypoparathyroidism and assisted reproductive technology: considerations while undergoing ovarian hyperstimulation
    Arkfeld, Christopher K.
    Mannstadt, Michael
    Mahalingaiah, Shruthi
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2024, 31 (06) : 197 - 202
  • [30] Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology
    Annalisa Racca
    Panagiotis Drakopoulos
    Ana Raquel Neves
    Nikolaos P. Polyzos
    Drugs, 2020, 80 : 973 - 994